Multiplatform Biomarker Discovery for Bladder Cancer Recurrence Diagnosis

Paoli, Marine De; Gogalic, Selma; Sauer, Ursula; Preininger, Claudia; Pandha, Hardev; Simpson, Guy R.; Horváth, András; Marquette, Christophe A.

doi:10.1155/2016/4591910

Cited by 11 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, De Paoli et al [95] analyzed the potential of multiple biomarkers (including HER2) for BC recurrence diagnosis on urine samples from NMIBC patients. Since no single biomarker candidate achieved an acceptable performance by itself, the authors identified several multivariable regression models; the best performing one (area under the curve 0.91) comprised both clinical (number of past recurrences, number of BCG therapies, stage at time of diagnosis) and molecular parameters, including HER2, which yielded the highest area under the curve value (0.7305) by itself.…”

Section: Survivalmentioning

confidence: 99%

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

et al. 2018

View full text Add to dashboard Cite

Although human epidermal growth factor receptor 2 (HER2) plays a prognostic and predictive role in breast and gastric cancer, its function in bladder cancer (BC) is still controversial. A comprehensive review of the literature has been carried out. An electronic search of databases from PubMed, Scopus, Google Scholar was implemented. The search terms were: “BC,” “bladder carcinoma,” “bladder neoplasm,” “human epidermal growth factor 2,” “HER2,” “HER-2,” “c-erbB-2,” “c-erbB2,” “erbB-2,” “erbB2,” “neu,” “marker,” “biomarker,” and “prognosis”. Results of the review consented to (a) summarize the available data on HER2 a predictor of recurrence and/or progression free survival on univariate and multivariate analysis, (b) explore the related issues in assessing HER2 status on these tumor samples, since they may severely impair its predictive function, and (c) report the state-of-the art of HER2 as a putative therapeutic target in BC and especially non-muscle invasive BC. HER2 stands out for being a prognostic factor as well as a therapeutic target in various cancers. Data from the literature concerning its use in BC provide conflicting results, probably due to the inherent complexity of BC biology. Efforts should be made to establish a suitable tumor-specific scoring system, and to assess single drugs’ efficacy in well-designed clinical trials.

show abstract

Section: Survivalmentioning

confidence: 99%

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Next, for each of this cancer associated processes biomarkers representing them were selected. Multiplexed assays for the panel were established in urine on a conventional microarray platform with fluorescence detection [ 83 ], and then transferred to a microtiter plate format enabling the easy automation of the developed multiplexed high-throughput assays and cost efficient colorimetric detection (see Figure 5 ) [ 119 ]. From an initial panel of 23 potential biomarkers, for seven no reagents in sufficient high quality were found, and those potential candidates had to be removed from the panel.…”

Section: Discussionmentioning

confidence: 99%

Analytical Protein Microarrays: Advancements Towards Clinical Applications

Sauer

2017

Sensors

Self Cite

View full text Add to dashboard Cite

Protein microarrays represent a powerful technology with the potential to serve as tools for the detection of a broad range of analytes in numerous applications such as diagnostics, drug development, food safety, and environmental monitoring. Key features of analytical protein microarrays include high throughput and relatively low costs due to minimal reagent consumption, multiplexing, fast kinetics and hence measurements, and the possibility of functional integration. So far, especially fundamental studies in molecular and cell biology have been conducted using protein microarrays, while the potential for clinical, notably point-of-care applications is not yet fully utilized. The question arises what features have to be implemented and what improvements have to be made in order to fully exploit the technology. In the past we have identified various obstacles that have to be overcome in order to promote protein microarray technology in the diagnostic field. Issues that need significant improvement to make the technology more attractive for the diagnostic market are for instance: too low sensitivity and deficiency in reproducibility, inadequate analysis time, lack of high-quality antibodies and validated reagents, lack of automation and portable instruments, and cost of instruments necessary for chip production and read-out. The scope of the paper at hand is to review approaches to solve these problems.

show abstract

“…Several papers reported that HER2 positivity may predict muscle invasion in urothelial cancer of the urinary bladder (33,34,35). Based on previous studies regarding HER2 involvement in tumor progression from bladder cancer, this oncoprotein was included in newly designed multiplatform biomarkers designed to be used in clinical practice to predict invasion and reccurence in patients with urothelial cancer (36,37,38). Our data support the HER2 role in the local invasion of urothelial tumors, most of the cases scored as +2 and +3 being staged into T3 (a or b) group.…”

Section: Discussionmentioning

confidence: 99%